eGenesis, a biotechnology company developing engineered organs to address the global organ shortage, raised $191 million in Series B funding.
Lux Capital led the investment round with participation from existing investors, including ARCH Ventures, Khosla Ventures, and Farallon Capital Management, alongside new investors such as DaVita, Eisai Innovation, and NATCO Pharmaceuticals.
eGenesis specializes in creating human-compatible organs through advanced genome engineering. The company’s lead candidate, EGEN-2784, is a porcine-derived kidney designed for safe transplantation in humans. The porcine-derived kidney incorporates specific genetic edits to prevent rejection, control immune responses, and neutralize viral risks from the donor animal.
According to the official press announcement, eGenesis will use the new funds to primarily support the advancement of its EGEN-2784 into first-in-human clinical studies, furthering its mission to develop transplantable organs as a transformative solution for organ failure. The company recently achieved a successful porcine kidney transplant authorized by the FDA and conducted at Massachusetts General Hospital.